In 2017, the North American Menopause Society (NAMS) issued an updated statement related to the current recommendations for best practices in using HT (hormone therapy) for the treatment of menopause-related symptoms such as vasomotor symptoms (VMS). The 2017 Hormone Therapy Position Statement of the North American Menopause Society (NAMS) is an update to the previous statement issued in 2012.
This Self-Learning program has been accredited by the Canadian Nurses Association for up to 1 credit hours. This program has been reviewed and developed by Canadian Nurses Association.
Chrissy Rowan, RN, MN, CDE, NP(c)
Aline G. Godcher, RN, MSCN, CCPE, OIIQ license 201-1307
Jennifer Beaveridge, MScN, DNP(c), NP-F
After completion of the program, participants will be able to:
- Describe the importance of managing moderate-to-severe vasomotor symptoms associated with menopause.
- Manage moderate-to-severe vasomotor symptoms in menopause in accordance with the 2017 NAMS position statement and in collaboration with the healthcare team.
- Describe the safety profiles of the management options for vasomotor symptoms in menopause.
- Describe various vasomotor symptoms associated with menopause.
- Identify various risk factors associated with vasomotor symptoms during menopause.
- Differentiate between vasomotor symptoms related to menopause from other diagnoses such as depression, insomnia, infectious diseases, and thyroid dysfunction.